Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026)
Xeris Biopharma Holdings' (XERS) quarterly Amortization of Deferred Charges came in at $900000.0 in Q1 2026, up 12.5% YoY from $800000.0 in Q1 2025, and up 145.69% on a QoQ basis from -$2.0 million in Q4 2025.
Xeris Biopharma Holdings (XERS) Amortization of Deferred Charges (2020 - 2026) Analysis & Trends
Xeris Biopharma Holdings (XERS) has 7 years of Amortization of Deferred Charges data on file, last reported at $900000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges rose 12.5% year-over-year to $900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $530000.0 (down 83.47% YoY) and the FY2025 annual result came in at $537000.0, down 82.14% from the prior year.
- Amortization of Deferred Charges climbed to $900000.0 in Q1 2026, from -$2.0 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $900000.0 in Q1 2026 to a low of -$2.0 million in Q4 2025.
- A 5-year average of $454235.3 and a median of $600000.0 in 2023 frame the typical range for Amortization of Deferred Charges.
- The widest YoY moves for Amortization of Deferred Charges: up 351.98% in 2025, down 344.11% in 2025.
- Tracing XERS's Amortization of Deferred Charges over 5 years: stood at $489000.0 in 2022, then climbed by 2.25% to $500000.0 in 2023, then soared by 61.4% to $807000.0 in 2024, then tumbled by 344.11% to -$2.0 million in 2025, then soared by 145.69% to $900000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $900000.0 (Q1 2026), -$2.0 million (Q4 2025), and $800000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Xeris Biopharma Holdings | 1.51 Bn | 1.39 Bn | 79.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 900,000.00 |
| Jun 30, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Mar 31, 2026 | 900,000.00 |
| Dec 31, 2025 | -1.97 Mn |
| Dec 31, 2025 | -1.97 Mn |
| Sep 30, 2025 | 800,000.00 |
| Sep 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Jun 30, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Mar 31, 2025 | 800,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Dec 31, 2024 | 807,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Sep 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Jun 30, 2024 | 800,000.00 |
| Mar 31, 2024 | 177,000.00 |
| Mar 31, 2024 | 177,000.00 |